Combination therapy of endocrinotherapy and targeted therapy is effective in treatment of premenopausal breast cancer patients
Samsung Medical Center Professor Yeon Hee Park of Division of Hematology-oncology gave a presentation of clinical results of Young-PEARL(KCSG-BR 15-10) conducted in premenopausal hormone receptor positive (HR+) metastatic breast cancer patients at the ASCO 2019 (American Society of Clinical Oncology) held in Chicago, United States.
The presentation showed that a combination therapy of CDK4/6 inhibitor Palbociclib and endocrine system drugs is more effective than Capecitabine, which is one of the widely used chemotherapies, in premenopausal patients, suggesting that a combination therapy of targeted therapy and endocrine inhibitor can be a great standard treatment for postmenopausal as well as premenopausal patients.
This study is a prospective clinical study that compared the combination therapy of endocrinotherapy and CDK4/6 inhibitor with chemotherapy in premenopausal HR+ metastatic breast cancer patients for the first time in the world. The 17-month follow-up study found that the progression-free survival (PFS) of Ibrance (Palbociclib) and endocrinotherapy is 20.1 months, showing that it reduced the disease progression and mortality risks by 34% compared to 14.4-month PFS of the chemotherapy group.